Frankie L. Stinson

Array ( [id] => 12580908 [patent_doc_number] => 20180085465 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-29 [patent_title] => METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES [patent_app_type] => utility [patent_app_number] => 15/816646 [patent_app_country] => US [patent_app_date] => 2017-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41934 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 238 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15816646 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12728521 [patent_doc_number] => 20180134674 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-17 [patent_title] => MAGL INHIBITORS [patent_app_type] => utility [patent_app_number] => 15/814322 [patent_app_country] => US [patent_app_date] => 2017-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42541 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 266 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15814322 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14836103 [patent_doc_number] => 20190276452 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => SELECTIVE INHIBITORS OF GENTOTOXIC STERESS-INDUCED IKK/NF-KB PATHWAYS [patent_app_type] => utility [patent_app_number] => 16/349580 [patent_app_country] => US [patent_app_date] => 2017-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34172 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 236 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16349580 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13026325 [patent_doc_number] => 10035778 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-31 [patent_title] => Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists [patent_app_type] => utility [patent_app_number] => 15/812986 [patent_app_country] => US [patent_app_date] => 2017-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 28563 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15812986 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13440647 [patent_doc_number] => 20180271866 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => 3-(SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 15/809107 [patent_app_country] => US [patent_app_date] => 2017-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22479 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15809107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14913603 [patent_doc_number] => 10428108 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-01 [patent_title] => Difluoroketamide derivatives [patent_app_type] => utility [patent_app_number] => 15/805521 [patent_app_country] => US [patent_app_date] => 2017-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12891 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 273 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15805521 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16861674 [patent_doc_number] => 11020396 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-01 [patent_title] => Pyrimidinone derivatives as Cdc7 inhibitors [patent_app_type] => utility [patent_app_number] => 16/348073 [patent_app_country] => US [patent_app_date] => 2017-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36452 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 559 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16348073 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12702067 [patent_doc_number] => 20180125855 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY [patent_app_type] => utility [patent_app_number] => 15/806165 [patent_app_country] => US [patent_app_date] => 2017-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46207 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15806165 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15407885 [patent_doc_number] => 20200024264 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES [patent_app_type] => utility [patent_app_number] => 16/348797 [patent_app_country] => US [patent_app_date] => 2017-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 135232 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16348797 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16842820 [patent_doc_number] => 11014892 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-25 [patent_title] => 5HT1F receptor agonists and mitochondrial biogenesis [patent_app_type] => utility [patent_app_number] => 16/347163 [patent_app_country] => US [patent_app_date] => 2017-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 9782 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16347163 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17571063 [patent_doc_number] => 11319321 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-03 [patent_title] => [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors [patent_app_type] => utility [patent_app_number] => 16/346745 [patent_app_country] => US [patent_app_date] => 2017-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16562 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 200 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16346745 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12680650 [patent_doc_number] => 20180118716 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => Chemical Process [patent_app_type] => utility [patent_app_number] => 15/796615 [patent_app_country] => US [patent_app_date] => 2017-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20709 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15796615 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15023283 [patent_doc_number] => 20190322646 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-24 [patent_title] => CRYSTALLINE FORMS OF AP26113, AND PREPARATION METHOD THEREOF [patent_app_type] => utility [patent_app_number] => 16/344443 [patent_app_country] => US [patent_app_date] => 2017-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5604 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16344443 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16786021 [patent_doc_number] => 10988433 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-27 [patent_title] => Cyclohexyl GPR40 agonists for the treatment of type II diabetes [patent_app_type] => utility [patent_app_number] => 16/342697 [patent_app_country] => US [patent_app_date] => 2017-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44138 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16342697 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12183998 [patent_doc_number] => 20180042935 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'THERAMUTEIN MODULATORS' [patent_app_type] => utility [patent_app_number] => 15/789476 [patent_app_country] => US [patent_app_date] => 2017-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 27386 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15789476 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16321270 [patent_doc_number] => 10781226 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-22 [patent_title] => Photoactivatable cancer prodrug [patent_app_type] => utility [patent_app_number] => 16/757370 [patent_app_country] => US [patent_app_date] => 2017-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 4922 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 125 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16757370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14777773 [patent_doc_number] => 20190263784 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => HETEROCYCLIC COMPOUND [patent_app_type] => utility [patent_app_number] => 16/342892 [patent_app_country] => US [patent_app_date] => 2017-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8595 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16342892 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12185408 [patent_doc_number] => 20180044345 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/785613 [patent_app_country] => US [patent_app_date] => 2017-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4460 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15785613 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16941013 [patent_doc_number] => 11053234 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-06 [patent_title] => 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors [patent_app_type] => utility [patent_app_number] => 16/341113 [patent_app_country] => US [patent_app_date] => 2017-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 114541 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 5 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16341113 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12621366 [patent_doc_number] => 20180098952 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-12 [patent_title] => INACTIVATORS OF TOXOPLASMA GONDII ORNITHINE AMINOTRANSFERASE FOR TREATING TOXOPLASMOSIS AND MALARIA [patent_app_type] => utility [patent_app_number] => 15/728714 [patent_app_country] => US [patent_app_date] => 2017-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20979 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15728714 [rel_patent_id] =>[rel_patent_doc_number] =>)